Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of extended-release guanfacine in children and adolescents with ADHD
2010-018579-12Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Takeda. Primary endpoint: Primary efficacy endpoint. Started Oct 2010; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2010-018579-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018579-12.